Hennigsdorf, January 20, 2022 - The medical technology company Pentracor GmbH from Hennigsdorf (convertible bond ISIN: DE000A289XB9, WKN: A289XB) has employed Rainer Mohr as a new Chief Financial Officer (CFO) since January 1, 2022.
In this function, Rainer Mohr controls and implements the strategic development of the company in all commercial and financial areas in close coordination and cooperation with the management of Pentracor. Together with the management, he will coordinate financial communication with the stakeholders and be the contact person for this target group. He is also responsible for controlling and managing the commercial areas of Pentracor GmbH. He reports to the managing director Dr. Ahmed Sheriff.
Rainer Mohr was entrusted with management and board positions in commercial and financial areas in medium-sized companies as well as in listed corporations. Among other things, he worked for Babcock Borsig Energie, Balcke-Dürr, Sovello AG and Balda AG. Rainer Mohr also took on management tasks in medical technology companies as an interim manager.
About the Pentracor GmbH
Pentracor GmbH, a medical technology company in Brandenburg, develops, produces and markets with PentraSorb® CRP the only selectively effective adsorber for removing an inflammatory protein from the blood plasma. Immune adsorption in the event of inflammation is thus becoming an effective therapy for excessive inflammatory reactions in a wide variety of clinical pictures. Selective CRP apheresis is one of the most promising innovations in medical technology. In November 2021, the company was awarded the most important business prize in the state of Brandenburg, the “Brandenburg Future Prize” 2021.